



February 9, 2023

CYTORI THERAPEUTICS INC.
Attention: James Vagner
HARMAC MEDICAL PRODUCTS, INC.
2201 Bailey Ave.
Buffalo, NY 1421

Re: BK220689 (Formally K092923)
Trade/Device Name: CYTORI PUREGRAFT 250/PURE SYSTEM
Regulation Number: 21 CFR 878.5040
Regulation Name: Suction lipoplasty system
Regulatory Class: Class II
Product Code: QKL

Dear Mr. Vagner:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated January 6, 2010. Specifically, FDA is updating this SE Letter because FDA has assigned your submission a new submission tracking number and created a new product code to better categorize your device technology.

Please update the registration and listing of the device within the FURLS Device Registration and Listing Module according to <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/RegistrationandListing/cm053185.htm>

For more information, please refer to the Federal Register Notice *Consolidation of Devices That Process Autologous Human Cells, Tissues, and Cellular and Tissue-Based Products at the Point of Care To Produce a Therapeutic Article* (86 FR 50887, available at <https://www.federalregister.gov/documents/2021/09/13/2021-18912/consolidation-of-devices-that-process-autologous-human-cells-tissues-and-cellular-and-tissue-based>).

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact the Regulatory Project Manager, Julia Russell at 240-704-0618 or by email at Julia.Russell@fda.hhs.gov.

Sincerely,

Wilson W. Bryan, MD
Director
Office of Tissues and Advanced Therapies
Center for Biologics Evaluation and Research

Enclosures